Advertisement
UK markets close in 1 hour 33 minutes
  • FTSE 100

    8,199.32
    +57.17 (+0.70%)
     
  • FTSE 250

    20,373.17
    +213.45 (+1.06%)
     
  • AIM

    778.21
    +3.28 (+0.42%)
     
  • GBP/EUR

    1.1827
    -0.0008 (-0.07%)
     
  • GBP/USD

    1.2714
    +0.0010 (+0.08%)
     
  • Bitcoin GBP

    50,974.51
    -356.59 (-0.69%)
     
  • CMC Crypto 200

    1,343.33
    -46.07 (-3.31%)
     
  • S&P 500

    5,484.99
    +11.76 (+0.21%)
     
  • DOW

    38,851.99
    +73.89 (+0.19%)
     
  • CRUDE OIL

    80.81
    +0.48 (+0.60%)
     
  • GOLD FUTURES

    2,333.20
    +4.20 (+0.18%)
     
  • NIKKEI 225

    38,482.11
    +379.67 (+1.00%)
     
  • HANG SENG

    17,915.55
    -20.57 (-0.11%)
     
  • DAX

    18,138.04
    +69.83 (+0.39%)
     
  • CAC 40

    7,630.20
    +58.63 (+0.77%)
     

Dynavax to Present at Upcoming Investor Conferences

EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June:

(PRNewsfoto/Dynavax Technologies)
(PRNewsfoto/Dynavax Technologies)
  • William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT

  • Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 p.m. ET

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

ADVERTISEMENT

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:
Paul Cox
pcox@dynavax.com 
510-665-0499

Nicole Arndt
narndt@dynavax.com,  510-665-7264

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-upcoming-investor-conferences-302157153.html

SOURCE Dynavax Technologies